Formación Académica y Profesional
Licenciado Matemáticas (Especialidad Fundamentales) por UCM, MBA Executive, MBA Financial Markets, Project Management Excellence Certified
Financial Markets Services Consulting, IT CIO ACO Grupo Santander, IBM Global Services Principal, Electronic Data System Client Ececutive

Welcome

The mathematician of the Complutense University of Madrid, José-Vidal Ruiz Varela, argues that Europe must raise its borrowing limit, leaving its deflationary policy. Meanwhile, USA must correct debt and raise the interest rates. Raising the interest rates in the USA and dropping them in Europe, recovers the European domestic demand and EE.UU may return to invest in Europe, with a stronger dollar, without any problem, generating hundreds of thousands of Jobs

Curso Superior Especialización Mercados. e-mail : admin@fasesdelabolsa.net

Curso Superior Especialización Mercados. e-mail : admin@fasesdelabolsa.net
14 horas en total, con clases presenciales o no, para llegar al Conocimiento comprobado y fiable de la situación de los mercados, basado en Teoremas y Fórmulas Matemáticas y la experiencia de día a día de trading. Al finalizar los alumnos se dan de alta en dominio privado. Entradas y Salidas en diferentes mercados de valores con números mágicos.

Productos y Servicios Bancarios, Bolsas Internacionales, Mercados de Capitales

Productos y Servicios Bancarios, Bolsas Internacionales, Mercados de Capitales
@fasesdelabolsa

Plan de Educación Financiera para Chicos y Personas entre 15 y 65 años

Plan de Educación Financiera para Chicos y Personas entre 15 y 65 años
@fasesdelabolsa

Agenda Macro

Agenda de Economía y Finanzas en el Calendario Económico de Investing.com Español.

PULSO DE MERCADOS

Principales Materias Primas


Commodities entregados por Forexpros.es

Cotización de las Principales divisas en tiempo real

Cotización de las Principales divisas en tiempo real
e-mail : admin@fasesdelabolsa.net

Principales Índices Mundiales


El IBEX 35 y los Índices del Mundo son proveídos por Investing.com Español.

Pfizer profit soars on gains, but revenue falls : Urgent Report

Pfizer Inc.'s second-quarter earnings quadrupled as asset-sale gains and other items overshadowed the drug maker's steeper-than-expected revenue decline
Pfizer's profit has improved in recent quarters as it worked to bounce back from the 2011 loss of U.S. exclusivity for blockbuster cholesterol-cutting drug Lipitor by cutting costs and bringing new drugs to market
At the same time, the company has pursued shareholder friendly actions such as shedding nonpharmaceutical assets and using the proceeds to repurchase its shares
Pfizer's former animal-health unit, Zoetis Inc. (ZTS), completed its roughly $2.2 billion initial public offering in February
Pfizer split off its remaining interest in the former unit last month through a voluntary exchange offer with its shareholders
Pfizer reported a profit of $14.1 billion, or $1.98 a share, up from $3.25 billion, or 43 cents, a year earlier
Excluding items such as asset-sales gains, acquisition costs and restructuring charges, adjusted earnings fell to 56 cents a share from 59 cents a share
Revenue dropped 7.1% to $12.97 billion
Analysts polled by Thomson Reuters had most recently forecast per-share earnings of 55 cents on revenue of $13.01 billion
Operating margin improved to 41.3% from 29.9%
Lipitor sales dropped 55% to $545 millionwhile sales of its top seller, the pain drug Lyrica, rose 9.6% to $1.13 billion
Pfizer said Monday it will reorganize its commercial operations into three units, in a rejiggering that the drug maker says will help it focus on the evolving needs of its various markets but could eventually pave the way to splitting up the company
The changes, which take effect starting in January, establish units selling drugs for pain disorders and inflammatory diseases like rheumatoid arthritis; cancer and consumer products; and the products that lost patent protection or will through 2015
They mean that sales in emerging markets like China and India, once separate, will be conducted by each of the new units
Pfizer has been under pressure from some on Wall Street to split off its "value" business selling drugs like the cholesterol fighter Lipitor that lost patent protection and can't generate the heady growth that branded drugs can
Some analysts viewed the changes as a step closer toward such a separation
Yet a spokeswoman said the new moves weren't made with a split in mind
The company also backed its full-year guidance
Publicar un comentario